India's multiple myeloma therapeutics market was valued at $152 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $271 Mn in 2030. One of the main reasons propelling the growth of this market is the increase in prevalence, Increasing awareness, and screening programs. The Market is segmented by type, drug, and distribution channel. Some key players in this market are Natco Pharma, Cipla, Hetero Drugs, Biocon, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, Lupin, Cadila Healthcare, and others.
The India Multiple Myeloma Therapeutics Market was valued at $152 Mn in 2022 and is estimated to expand at a CAGR of 7.5% from 2022 to 2030 and will reach $271 Mn in 2030. Multiple myeloma is a kind of malignancy that affects bone marrow plasma cells. Multiple myeloma is one of the most rapidly spreading cancers in India, and its frequency is rising significantly. According to research by the Indian Council of Medical Research, the incidence of multiple myeloma in India is approximately 2 to 3 per 100,000 people, with the disease being more prevalent in the country's southern and western areas. In the future years, the Indian market for multiple myeloma therapies is anticipated to experience considerable expansion due to factors such as the disease's rising prevalence, rising awareness and screening programs, and the availability of sophisticated treatments.
Market Growth Drivers
The incidence of multiple myeloma in India is on the rise, which is a major growth driver for the market. According to the Indian Journal of Medical and Paediatric Oncology, the incidence of multiple myeloma in India is increasing at a rate of 10-15% annually. The aging population in India is increasing, which is also contributing to the growth of the multiple myeloma therapeutics market. As people age, the risk of developing multiple myeloma increases. The Indian government is increasing its healthcare spending, which is expected to boost the market for multiple myeloma therapeutics.
The government has launched several initiatives to improve healthcare access and affordability for the population, which is likely to increase the demand for multiple myeloma therapeutics. The development of new technologies and treatment methods is driving the growth of the multiple myeloma therapeutics market in India. The use of targeted therapies, immunomodulatory drugs, and stem cell transplantations has improved the survival rate and quality of life of patients with multiple myeloma. The awareness about multiple myeloma and screening programs has increased in India, which is expected to drive the growth of the market. The Indian government has launched several initiatives to raise awareness about multiple myeloma, which is expected to increase the demand for therapeutics.
A significant challenge in India is limited access to healthcare, particularly in rural areas, which can result in delays in the diagnosis and treatment of multiple myeloma. Multiple myeloma is a relatively rare disease, and many patients may not be aware of the condition and its symptoms, resulting in a delayed diagnosis and poor outcomes. The cost of treatment for multiple myeloma can be high, making it difficult for many patients to access the necessary care. The availability of multiple myeloma medications in India is limited, which can result in delays in treatment and limited treatment options. The infrastructure for diagnosing and treating multiple myeloma in India can be inadequate, particularly in rural areas, which can limit access to care and result in poor outcomes. There is a shortage of healthcare professionals in India, including oncologists, which can limit access to care and result in delays in diagnosis and treatment. The regulatory environment in India can be challenging for pharmaceutical companies, which can result in delays in drug approvals and limited access to innovative therapies.
In India, the healthcare policy and regulatory landscape is overseen by several bodies, including the Ministry of Health and Family Welfare (MOHFW), the Central Drugs Standard Control Organization (CDSCO), and the National Pharmaceuticals Pricing Authority (NPPA). The MOHFW is responsible for the formulation of policies, the implementation of programs, and the regulation of healthcare services. The CDSCO is responsible for the regulation of drugs and medical devices, including the approval and licensing of new drugs. The NPPA is responsible for controlling the prices of drugs and ensuring their availability.
The Indian government has implemented several policies aimed at promoting healthcare in the country, including the Ayushman Bharat scheme, which aims to provide free healthcare to over 100 Mn families. The government has also launched the National Health Stack, which is a collection of digital health services aimed at making healthcare more accessible and affordable for all Indians.
In terms of the regulatory landscape, India follows a drug approval process that is similar to that of the US FDA. The CDSCO has established guidelines for the conduct of clinical trials in the country. These guidelines require that all clinical trials be conducted in accordance with the International Conference on Harmonization-Good Clinical Practice (ICH-GCP) guidelines. The CDSCO also requires that all drugs undergo clinical trials in India before they can be approved for marketing.
In India, the reimbursement scenario for multiple myeloma therapeutics is largely dependent on the type of health insurance coverage that patients have. The public health insurance system, known as the Pradhan Mantri Jan Arogya Yojana (PMJAY) or Ayushman Bharat, provides free treatment to eligible patients for a select number of diseases, including cancer. However, the coverage is limited, and patients may not receive the full range of treatments available.
Private health insurance plans are also available in India, but their coverage and reimbursement policies can vary widely depending on the plan and the provider. Some plans may cover a limited range of treatments, while others may cover more comprehensive treatment options.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
22.214.171.124 Product Applications and Services
126.96.36.199 Recent Developments
188.8.131.52 Partnerships Ecosystem
184.108.40.206 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Distribution Channel
By End User (Revenue, USD Bn):
By Drug Class
Immunomodulatory Drugs (IMiDs)
One of the most common therapies used to treat myeloma is immunomodulatory drugs or IMiDs. These drugs work by modifying the immune system to attack myeloma cells and have been a significant advance in the treatment of multiple myeloma. Some of the commonly used IMiDs in multiple myeloma include:
Proteasome inhibitors are a class of drugs that are commonly used in the treatment of multiple myeloma. They work by blocking the activity of proteasomes, which are cellular structures that break down proteins. This leads to the accumulation of proteins within the myeloma cells, ultimately causing their death. Some proteasome inhibitors used in multiple myeloma include:
Monoclonal antibodies, target specific proteins on the surface of myeloma cells, causing them to be destroyed by the immune system. Some of the commonly used monoclonal antibodies in multiple myeloma include:
Chemotherapy drugs work by killing rapidly dividing cells, including cancer cells. Chemotherapy is often used in combination with other drugs, such as steroids, immunomodulatory drugs, or proteasome inhibitors, to improve their effectiveness. Here are some chemotherapy drugs used in multiple myeloma:
Steroids such as dexamethasone and prednisone are often used in combination with other drugs to treat multiple myeloma. They can reduce inflammation, suppress the immune system, and promote the death of myeloma cells.
Steroids are effective in reducing inflammation and suppressing the immune system, which can help to control the growth of myeloma cells. However, they can have side effects, such as weight gain, mood changes, and increased risk of infection, so their use needs to be carefully monitored.
Other drug classes used to treat multiple myeloma include:
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to oﬀer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses